Sign In
Buy TNDM
$18.03
-0.570 (-3.06%)
At Close: Jun 03, 2026
Why Tandem Diabetes Care Stock Is Cratering Today
04:39pm, Thursday, 04'th Aug 2022 The Motley Fool
The diabetes specialist's Q2 financial report isn't sitting well with investors.
What 4 Analyst Ratings Have To Say About Tandem Diabetes Care
04:01pm, Thursday, 04'th Aug 2022 Benzinga
Analysts have provided the following ratings for Tandem Diabetes Care (NASDAQ:TNDM) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
3
0
Tandem Diabetes (TNDM) Q2 Earnings Miss, Sales View Cut
12:40pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Factoring the pandemic and competitive pressure as well as the evolving economic environment, including inflation and the threat of recession, Tandem Diabetes (TNDM) cuts its full-year guidance.
Why Tandem Diabetes Care Stock Is Cratering Today
12:39pm, Thursday, 04'th Aug 2022
The diabetes specialist's Q2 financial report isn't sitting well with investors.
Tandem Diabetes Care, Inc. (TNDM) CEO John Sheridan on Q2 2022 Results - Earnings Call Transcript
11:02pm, Wednesday, 03'rd Aug 2022
Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Susan Morrison - Executive VP & Chief Administrative Officer John Sheridan - P
Implied Volatility Surging for Tandem Diabetes Care (TNDM) Stock Options
02:30pm, Wednesday, 13'th Jul 2022 Zacks Investment Research
Investors need to pay close attention to Tandem Diabetes Care (TNDM) stock based on the movements in the options market lately.
Tandem Diabetes Care to Announce Second Quarter 2022 Financial Results on August 3, 2022
04:05pm, Tuesday, 12'th Jul 2022
SAN DIEGO--(BUSINESS WIRE)---- $TNDM--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2022 results after the
Tandem Diabetes Care: Strong Financials And Revenue, Overpenalized For Missed Earnings
10:50am, Friday, 08'th Jul 2022
TNDM revenue continues to grow as the company increases market share in an expanding industry. Mixed Q4 2021 and Q1 2022 earnings, coupled with the overall market downturn, have created an extremely l
Tandem Diabetes (TNDM) New Launches Aid Growth Amid Cost Woes
01:13pm, Wednesday, 06'th Jul 2022 Zacks Investment Research
Tandem Diabetes (TNDM) witnesses strong customer retention, driven by the impressive positive response from the Control-IQ technology.
Tandem Diabetes (TNDM) New Launches Aid Growth Amid Cost Woes
10:54am, Wednesday, 06'th Jul 2022
Tandem Diabetes (TNDM) witnesses strong customer retention, driven by the impressive positive response from the Control-IQ technology.
CVRx (CVRX) Soars 5.6%: Is Further Upside Left in the Stock?
01:23pm, Monday, 27'th Jun 2022 Zacks Investment Research
CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Tandem Diabetes (TNDM) Global Pump Sales Aid, Price Issue Ails
01:31pm, Friday, 24'th Jun 2022 Zacks Investment Research
Tandem Diabetes (TNDM) is witnessing strong customer retention, driven by the impressive positive response from the Control-IQ technology.
Tandem Diabetes (TNDM) Global Pump Sales Aid, Price Issue Ails
10:55am, Friday, 24'th Jun 2022
Tandem Diabetes (TNDM) is witnessing strong customer retention, driven by the impressive positive response from the Control-IQ technology.
Here's Why Investors Should Retain Tandem Diabetes (TNDM) Now
04:10pm, Wednesday, 22'nd Jun 2022 Zacks Investment Research
Investors are optimistic about Tandem Diabetes' (TNDM) strong pump shipments and ongoing product innovations.
Here's Why Investors Should Retain Tandem Diabetes (TNDM) Now
01:55pm, Wednesday, 22'nd Jun 2022
Investors are optimistic about Tandem Diabetes' (TNDM) strong pump shipments and ongoing product innovations.
